Modulating CD27 signaling to treat cancer

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1604-1606

  Riether, Carsten ^a   Schürch, Christian ^a   Ochsenbein, Adrian F ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cancer; CD27; Leukemia stem cell; Regulatory T cells; Tumor infiltrating lymphocytes

Indexed keywords

ANTIBODY; B LYMPHOCYTE RECEPTOR; BETA CATENIN; CD27 ANTIBODY; CD27 ANTIGEN; CD70 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; WNT PROTEIN;

BRAIN CANCER; CANCER STEM CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; FIBROSARCOMA; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOMA; MACROPHAGE; MELANOMA; NATURAL KILLER CELL; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886943333     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21425     Document Type: Note

References (10)

1. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17:275-81; PMID:15886117; http://dx.doi.org/10.1016/j.coi.2005.04.004.
2. Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009; 229:216-31; PMID:19426224; http://dx.doi.org/10.1111/j.1600-065X.2009.00774.x.
3. Matter M, Odermatt B, Yagita H, Nuoffer JM, Ochsenbein AF. Elimination of chronic viral infection by blocking CD27 signaling. J Exp Med 2006; 203:2145-55; PMID:16923852; http://dx.doi.org/10.1084/jem.20060651.
4. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 2007; 110:2537-44; PMID:17615291; http://dx.doi.org/10.1182/blood-2007-03-082578.
5. Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN, et al. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med 2004; 199:1595-605; PMID:15184507; http://dx.doi.org/10.1084/jem.20031111.
6. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007; 109:4810-5; PMID:17311995; http://dx.doi.org/10.1182/blood-2006-11-057216.
7. Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 2010; 33:769-79; PMID:20842060; http://dx.doi.org/10.1097/CJI.0b013e3181ee238f.
8. Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth. Cancer Res 2012; PMID:22628427; http://dx.doi.org/10.1158/0008-5472.CAN-11-2791.
9. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411:1058-64; PMID:11429607; http://dx.doi.org/10.1038/35082583.
10. Schürch C, Riether C, Matter MS, Tzankov A, Ochsenbein AF. CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J Clin Invest 2012; 122:624-38; PMID:22232214; http://dx.doi.org/10.1172/JCI45977.